The impact of metabolic syndrome impact on the progression of Parkinson?s Disease: Preliminary results in the PPMI study database.

LUCAS UDOVIN (PRIMERA AUTORÍA COMPARTIDA); MARÍA INÉS HERRERA (PRIMERA AUTORÍA COMPARTIDA); GUENSON CHEVALIER; MATILDE OTERO-LOSADA; SOFIA BORDET; CECILIA QUARRACINO; CAPANI FRANCISCO; SANTIAGO PEREZ-LLORET

Congreso; XXXVI Congreso Anual de la SAN (MODALIDAD VIRTUAL); 2021

Introduction. Metabolic syndrome (MetS) and Parkinson?s disease (PD) share common pathophysiological mechanisms. This study aimed to investigate the contribution of MetS on the progression of Parkinson?s Disease. Methods. We included 423 newly diagnosed PD patients, free from antiparkinsonian treatment, from the Parkinson?s Progress Marker Initiative (PPMI) study database. We compared the changes in MDS-UPDRS total score (a marker of disease severity) and sub-scores in PD patients with or without MetS during the first five years of follow-up. Results. As shown in Table 1, PD patients with MetS were more frequency males. Patients with PD and MetS showed higher MDS-UPDRS total scores at baseline and during the whole follow-up as compared to those without (Figure 1, Table 2). Similarly, PD patients with MetS had higher MDS-UPDRS part III subscore (motor symptoms) at baseline and during the whole follow-up (Table 2). Conclusions. We observed that patients with MetS suffered from a more severe Parkinson?s Disease, manifested by higher MDS-UPDRS total score at the clinical diagnosis of the disease and during the first five years of follow-up. These preliminary results suggest that MetS may contribute to the neurodegenerative process of Parkinson?s Disease.